EP0969842A1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
EP0969842A1
EP0969842A1 EP98912622A EP98912622A EP0969842A1 EP 0969842 A1 EP0969842 A1 EP 0969842A1 EP 98912622 A EP98912622 A EP 98912622A EP 98912622 A EP98912622 A EP 98912622A EP 0969842 A1 EP0969842 A1 EP 0969842A1
Authority
EP
European Patent Office
Prior art keywords
composition
active ingredient
buspirone
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98912622A
Other languages
German (de)
French (fr)
Inventor
Richard David Green
Edward Stewart Johnson
Jonathan Ernest Lacy
Nicholas John Mallard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RP Scherer Technologies LLC
Original Assignee
Catalent UK Swindon Encaps Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent UK Swindon Encaps Ltd filed Critical Catalent UK Swindon Encaps Ltd
Publication of EP0969842A1 publication Critical patent/EP0969842A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to a pharmaceutical composition, a process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders, sleep apnoea and/or related respiratory disorders and/or substance addiction, especially alcohol abuse, the treatment and/or prophylaxis of incontinence disorders, inducing immunosuppression and/or treating immune disorders, the alleviation of extrapyramidal motor disorders and/or as a memory enhancer.
  • Buspirone (8- [4- [4- (2-pyrimidinyl) -1- piperazinyl] butyl] -8-azaspiro [ .5] decane-7, 9-dione) has been shown to be effective in the treatment of anxiety. The mechanism of action of buspirone has not been fully elucidated. However, it is known that buspirone is a 5- WI 1 agonist and, in particular, a potent 5-HT 1A agonist and it is thought that it is action at these receptors which may account for its anxiolytic activity.
  • Buspirone is currently administered orally in the form of a conventional tablet which is scored in a manner which provides for it to be broken into halves or thirds along breaklines, thus allowing for some titration of the dose.
  • each tablet or portion thereof is designed to be swallowed whole.
  • Doses range from 15 to 60 mg per day and may be delivered as 2 or 3 divided doses.
  • buspirone is absorbed from the gastrointestinal tract, that is, the stomach, the small intestine and the proximal large intestine (colon) , into the hepatic portal system and is presented to the liver before reaching the systemic circulation.
  • the liver is known to be the principal site for conversion of active buspirone into metabolites and, indeed, buspirone is rapidly metabolised by the liver into a large number of metabolites.
  • buspirone is rapidly metabolised by the liver into a large number of metabolites.
  • twelve metabolites of buspirone were isolated from urine (see H. K. Jajoo et al, Drug Metabolism and Disposition, (1989) , 17 . , 634-640) .
  • 1- pyrimidinylpiperazine (1-PP) has been reported to possess any potential therapeutic activity and this compound is said to possess, at most, only 20% of the activity of unchanged buspirone as determined by the Vogel conflict test in rats (see R.E. Gammans et al, Am. J.Med. , (1986) , (suppl.3B) , 41-51).
  • buspirone The mean systemic availability of unchanged buspirone is thought to be about 4% after conventional oral administration and the plasma levels of this drug are said to exhibit great variability. This latter effect has been attributed to differences between individuals in pre-systemic metabolism, that is, metabolism in the gastrointestinal tract, in the membranes lining the gastrointestinal tract and also in the liver. However, it is clear that the clinical effectiveness of buspirone is compromised by the extensive pre-systemic metabolism of this drug which occurs following conventional oral administration.
  • Buspirone is an example from a class of compounds known as the azapirones which have been shown to be effective in the treatment of anxiety.
  • Other azapirones include , 4-dimethyl-1- [4- [4- (2-pyrimidinyl) -1- piperazinyl] butyl] -2 , 6-piperidinedione (gepirone) , 2- [4- [4- (2-pyrimidinyl) -1-piperazinyl] butyl] -1,2- benzisothiazol-3 (2H) -one 1,1-dioxide (ipsapirone) , (3a ⁇ ,4 ⁇ !,4a ⁇ , 6a ⁇ , 7 ⁇ ,7ac ⁇ ) -3a, 4 , 4a, 6a, 7, 7a-hexahydro-2- [4- [4- (2-pyrimidinyl) -1-piperazinyl] butyl] -4 , 7-etheno-lH- cyclobut [f] iso
  • agonists include (+) -N- [2- [4- [2,3-dihydro-2- (hydroxymethyl) -1,4- benzodioxin-5-yl] -1-piperazinyl] ethyl] -4-fluoro- benzamide (flesinoxan) , 2- [4- [4- (4-chloro-lH-pyrazol-l- yl) butyl] -1-piperazinyl] pyrimidine (lesopitron) , (R) -3,4-dihydro-N- (1-methylethyl) -3- ( (l- methylethyDpropylamino) -2H-l-benzopyran-5-carboxamide (ebalzotan) , N- [2- [4- (2-pyrimidinyl) -1- piperazinyl] ] adamantane-1-carboxamide (adatanserin) , (R) - 4- (dipropyla
  • a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HTi agonist, characterised in that the composition is formulated to reduce pre-systemic metabolism of the 5-HTi agonist.
  • pre-systemic metabolism of the active ingredient is to be reduced, it is important that the active ingredient is absorbed into the systemic circulation at a site which enables the active ingredient to avoid entering the portal circulation to the liver and thus avoid extensive metabolism by the liver (the so- called "first pass effect"). Since absorption from the gastrointestinal tract is known to result in the active ingredient entering the hepatic portal system to the liver, one option for reduction of pre-systemic metabolism is to promote absorption from sites before the active ingredient reaches the gastrointestinal tract. Accordingly, it is preferred that the composition of the invention is formulated to promote pre-gastric absorption of the 5-HTi agonist.
  • pre-gastric absorption is used to refer to absorption of the active ingredient from that part of the alimentary canal prior to the stomach and includes buccal, sublingual, oropharyngeal and oesophageal absorption.
  • composition of the invention is formulated to promote absorption of the active ingredient through the buccal, sublingual, pharyngeal and/or oesophageal mucous membranes.
  • the composition of the invention should be in a form which sustains the active ingredient in contact with the buccal, sublingual, pharyngeal and/or oesophageal mucous membranes .
  • the composition of the invention is in the form of a viscous emulsion, syrup or elixir, a sub-lingual tablet, a suckable or chewable tablet, softgel, lozenge, aqueous or non-aqueous drops or other dosage form designed to release the active ingredient in a controlled manner to saliva or to the buccal, pharyngeal and/or oesophageal mucous membranes, a fast- dispersing dosage form designed rapidly to release the active ingredient in the oral cavity, or a bioadherent system.
  • bioadherent system refers to a solid or liquid dosage form which, at body temperature, exhibits controlled release and bioadherence characteristics.
  • This type of dosage form may be an emulsion which is water in oil in nature and whose internal phase is greater than that of the external phase. Examples of such bioadherent systems may be found in U.S. Patent No. 5055303.
  • fast-dispersing dosage forms are particularly preferred since they will disintegrate rapidly in the mouth without the need for water, or other liquid, to aid swallowing. Such fast- dispersing dosage forms are therefore more convenient and easier for patients to take than conventional oral dosage forms.
  • the active ingredient is presented for absorption at a higher concentration than with conventional oral dosage forms.
  • use of such fast-dispersing dosage forms may allow a reduction in the dose required to achieve the desired therapeutic effect which, in turn, may result in a reduction in the incidence and/or severity of side effects. More reproducible plasma levels of the active ingredient may also be achieved with such dosage forms.
  • U.S. Patent No. 5120549 discloses a fast- dispersing matrix system which is prepared by first solidifying a matrix-forming system dispersed in a first solvent and subsequently contacting the solidified matrix with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, the matrix- forming elements and active ingredient being substantially insoluble in the second solvent, whereby the first solvent is substantially removed resulting in a fast-dispersing matrix.
  • U.S. Patent No. 5079018 discloses a fast- dispersing dosage form which comprises a porous skeletal structure of a water soluble, hydratable gel or foam forming material that has been hydrated with water, rigidified in the hydrated state with a rigidifying agent and dehydrated with a liquid organic solvent at a temperature of about 0°C or below to leave spaces in place of hydration liquid.
  • U.S. Patent No. 5298261 discloses fast-dispersing dosage forms which comprise a partially collapsed matrix network that has been vacuum-dried above the collapse temperature of the matrix. However, the matrix is preferably at least partially dried below the equilibrium freezing point of the matrix.
  • first polypeptide component and the second polypeptide component together comprise about 2% to 20% by weight of the particulate support matrix and wherein the bulking agent comprises about 60% to 96% by weight of the particulate support matrix; and wherein the second polypeptide component has a solubility in aqueous solution greater than that of the first polypeptide component and wherein the mass: mass ratio of the first polypeptide component to the second polypeptide component is from about 2 : 1 to about 1 : 14 ; and wherein when the support matrix is introduced into an aqueous environment the support matrix is disintegrable within less than about 20 seconds.
  • US Patent No. 5576014 discloses fast-dispersing dosage forms which dissolve intrabuccally and which comprise compressed moldings formed from granules comprising a saccharide having low moldability which has been granulated with a saccharide having high moldability. The resulting compressed moldings show quick disintegration in the buccal cavity.
  • EP-B-0690747 describes particles comprising an excipient forming a matrix and at least one active ingredient uniformly distributed in the mass of the matrix which are prepared by a process comprising the steps of preparing an homogeneous pasty mixture with a viscosity below 1 Pa . s , measured at room temperature (15- 20°C) , from at least one active ingredient, a physiologically acceptable hydrophilic excipient and water; extruding the resulting homogeneous mixture and cutting the extrudate to give moist particles; freezing the resulting particles as they fall under gravity through a stream of inert gas at a temperature below 0°C; and drying the particles by freeze drying.
  • Australian Patent No. 666666 discloses a rapidly disintegratable multiparticulate tablet having a mixture of excipients in which the active substance is present in the form of coated microcrystals or optionally coated microgranules . Such tablets disintegrate in the mouth in an extremely short time, typically less than 60 seconds.
  • 5382437 discloses a porous carrier material having sufficient rigidity for carrying and administering an active material which is capable of rapid dissolution by saliva and which is formed by freezing a liquefied ammonia solution comprising liquid ammonia, a liquid ammonia-soluble gel or foam material and a rigidifying agent for the gel or foam material selected from the group consisting of a monosaccharide, a polysaccharide and combinations thereof, and deammoniating the frozen material thus formed by causing material transfer of ammonia from the frozen state to the gas state thereby leaving spaces in the carrier material in place of the frozen ammonia.
  • WO 93/13758 (PCT/US92/07497) describes tablets of increased physical strength which are prepared by combining and compressing a meltable binder, excipients and a pharmaceutically active agent into a tablet, melting the binder in the tablet and then solidifying the binder.
  • a disintegrating agent is utilised to increase the disintegration rate of the tablet after oral intake.
  • a volatilisable component is used to form porous tablets. Some embodiments disintegrate in the mouth in less than 10 seconds.
  • US Patents Nos . 3885026 and 4134943 also disclose fast-dispersing porous tablets and a method for increasing their physical strength by first compressing the tablet and then volatilising a readily volatilisable solid adjuvant incorporated in the tablet to attain the desired porosity.
  • EP-A-0601965 describes a shearform matrix material which can be used, inter alia, to deliver a pharmaceutically active agent.
  • the shearform matrix is formed by increasing the temperature of a feedstock which includes a solid non-solubilised carrier material to the point where it will undergo internal flow with the application of a fluid shear force, ejecting a stream of the heated feedstock thus formed under pressure from an orifice and then subjecting the feedstock to disruptive fluid shear force which separates the flow of feedstock into multiple parts and transforms the morphology of the feedstock .
  • 5683720 discloses discrete particles containing a pharmaceutically active agent which can be fast-dispersing and are formed by subjecting a solid, organic feedstock to liquiflash conditions whereby the feedstock is transformed instantaneously from solid to liquiform to solid, liquiform being a transient condition in which the feedstock has substantially unimpeded internal flow. Shear force is then imparted to the liquiform feedstock in an amount sufficient to separate tiny masses of feedstock which then solidify as discrete particles.
  • fast-dispersing dosage form therefore encompasses, but is not limited to, all the types of dosage form described in the preceding paragraphs .
  • the fast- dispersing dosage form is of the type described in U.K. Patent No. 1548022, that is, a solid fast-dispersing dosage form comprising a network of the active ingredient and a water-soluble or water-dispersible carrier which is inert towards the active ingredient, the network having been obtained by subliming solvent from a composition in the solid state, that composition comprising the active ingredient and a solution of the carrier in a solvent .
  • the composition of the invention disintegrates within 1 to 60 seconds, more preferably 1 to 30 seconds, especially 1 to 10 seconds, and particularly 2 to 8 seconds, of being placed in the oral cavity.
  • the composition will preferably contain, in addition to the active ingredient, matrix forming agents and secondary components.
  • Matrix forming agents suitable for use in the present invention include materials derived from animal or vegetable proteins, such as the gelatins, dextrins and soy, wheat and psyllium seed proteins; gums such as acacia, guar, agar, and xanthan; polysaccharides; alginates; carboxymethylcelluloses; carrageenans; dextrans; pectins; synthetic polymers such as polyvinylpyrrolidone; and polypeptide/protein or polysaccharide complexes such as gelatin-acacia complexes .
  • matrix forming agents suitable for use in the present invention include sugars such as mannitol, dextrose, lactose, galactose and trehalose; cyclic sugars such as cyclodextrin; inorganic salts such as sodium phosphate, sodium chloride and aluminium silicates; and amino acids having from 2 to 12 carbon atoms such as a glycine, L-alanine, L-aspartic acid, L-glutamic acid, - hydroxyproline, L-isoleucine, L-leucine and L- phenylalanine .
  • sugars such as mannitol, dextrose, lactose, galactose and trehalose
  • cyclic sugars such as cyclodextrin
  • inorganic salts such as sodium phosphate, sodium chloride and aluminium silicates
  • amino acids having from 2 to 12 carbon atoms such as a glycine, L-alanine, L-a
  • One or more matrix forming agents may be incorporated into the solution or suspension prior to solidification.
  • the matrix forming agent may be present in addition to a surfactant or to the exclusion of a surfactant.
  • the matrix forming agent may aid in maintaining the dispersion of any active ingredient within the solution or suspension. This is especially helpful in the case of active agents that are not sufficiently soluble in water and must, therefore, be suspended rather than dissolved.
  • Suitable colouring agents include red, black and yellow iron oxides and FD & C dyes such as FD & C blue No. 2 and FD & C red No. 40 available from Ellis & Everard.
  • Suitable flavouring agents include mint, raspberry, liquorice, orange, lemon, grapefruit, caramel, vanilla, cherry and grape flavours and combinations of these.
  • Suitable pH modifiers include citric acid, tartaric acid, phosphoric acid, hydrochloric acid and maleic acid.
  • Suitable sweeteners include aspartame, acesulfame K and thaumatin.
  • Suitable taste-masking agents include sodium bicarbonate, ion-exchange resins, cyclodextrin inclusion compounds, adsorbates or microencapsulated actives.
  • compositions in accordance with this invention include a 5-HT 1A agonist, especially an azapirone or a salt thereof, as the active 5-HTi agonist. It is particularly preferred that the active 5-HTi agonist is buspirone or a salt thereof.
  • Buspirone which is absorbed by pre-gastric absorption or at a high rate across the stomach mucosa from a composition in accordance with this invention passes straight into the systemic circulatory system thereby avoiding first pass metabolism in the liver. Accordingly, the initial rapid production of unwanted, inactive metabolites is reduced and the bioavailability of active buspirone is increased.
  • the increased bioavailability of active buspirone means that the dose of buspirone may be reduced whilst still producing the desired beneficial effect. This will result in a further decrease in the production of unwanted metabolites and a reduction in the incidence and/or severity of side effects .
  • the active ingredient preferably is present in the composition in an amount of from 0.5 to 30%, more preferably 1 to 20%, by weight of the composition. It is also preferred that the active ingredient is present in the composition in an amount of from 0.25 to 50 mg, more preferably 0.5 to 10 mg and, especially, 1 to 10 mg.
  • a process for preparing a pharmaceutical composition as defined above which comprises bringing a carrier into association with the active ingredient.
  • the invention provides the use of a fast-dispersing dosage form designed to release active ingredient rapidly in the oral cavity to deliver a 5-HT j. agonist.
  • a method of administering a 5-HTi agonist to a patient which comprises introducing into the oral cavity of the patient a composition as previously defined is also provided.
  • the invention also provides, in another aspect, a composition as defined above for use in the treatment of anxiety.
  • the composition of the invention is also useful in the palliative treatment of anxiety neurosis, that is, neurosis with a preponderance of anxiety symptoms.
  • 5-HTi agonists especially the azapirones
  • 5-HTi agonists have also been evaluated in the treatment of depression, attention deficit disorder and panic disorders and as memory enhancers.
  • the azapirones, especially buspirone have been found to be useful in the treatment and/or prophylaxis of incontinence disorders associated with the gastrointestinal or urogenital tracts, such as urinary incontinence, faecal incontinence and urinary retention.
  • Such compounds are also useful for inducing immunosuppression and/or treating immune disorders and are therefore useful in the treatment of conditions such as contact, atopic or eczematous dermatitis and Sjogren's syndrome (including secondary keratoconjunctivitis sicca) , autoimmune diseases and diseases of known or unknown etiology having an immunological component or allergies, especially rheumatoid arthritis and, in particular, juvenile rheumatoid arthritis.
  • Such compounds may also be used in the treatment of sleep apnoea and related respiratory disorders, such as sudden infant death syndrome, and can also alleviate the symptoms of sleep apnoea such as anxiety, depression, fatigue, malaise, irritability, anger and hostility.
  • azapirones such as buspirone can be used in the treatment of substance addiction.
  • substance addiction includes over-eating, eating disorders and the habitual use of alcohol, tobacco, marijuana, cocaine, opiates, methadone, amphetamine, methphenidate and related designer drugs.
  • Such compounds are particularly useful in the treatment of alcohol abuse as they also reduce the craving for alcohol and can therefore be used for treating patients undergoing short term treatment of alcohol withdrawal and in chronic alcohol abusers .
  • Use of such compounds in the treatment of alcohol abuse avoids the enhancement or continuation of sensory impairment, the risk of developing drug dependence and the unpleasant effects of so-called aversion therapy.
  • such compounds produce behavioural modifications which include lessening of alcohol craving and ingestion and improvement of social functioning.
  • 5-HTi agonists have also been used in the treatment of social phobia, obsessive-compulsive disorder, migraine, cerebellar ataxia, levodopa-induced dyskinesias, Huntington's disease, central and peripheral neurodegenerative disorders, emesis, hypertension, hayfever, asthma and pruritis and to assist smokers in giving up smoking.
  • the 5-HT 1D agonists have been found to be especially useful in the treatment of migraine and related conditions .
  • This invention is further illustrated by the following examples.
  • Each blister was then coded with a batch number and overwrapped in a preformed sachet by placing the blister in the sachet and sealing the open end of the sachet completely.
  • Each sachet was then labelled with the product name, batch number, date of manufacture and suppliers name.
  • Each dosage unit had the following composition:
  • the aim of this experiment was to compare the bioavailability of the buspirone hydrochloride formulation of Example 1 with the commercially available tablet formulation of buspirone hydrochloride sold under the registered Trade Mark “Buspar” by Bristol-Myers Pharmaceuticals, Bristol-Myers Squibb House, 141-149 Staines Road, Hounslow, Middlesex, TW3 3JA, England.
  • An open label, randomised, crossover, volunteer study was performed as follows. Six fasted, healthy male subjects of ages between 18 and 40 years, giving written informed consent, underwent a thorough medical examination to establish their fitness to participate in the study. Subjects received study treatment in the order dictated by a pre-determined randomisation schedule. Subjects were given either the formulation of Example 1 or the "Buspar" formulation. Blood samples for determination of pharmacokinetic parameters were taken at baseline (immediately before drug administration) , then after 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 12 and 24 hours. The study procedures were repeated two weeks later, when subjects were crossed-over to receive their second drug administration.
  • Buspirone hydrochloride was administered as single 20 mg doses (made up from 2 x 10 mg tablets) of the formulation of Example 1 or of the "Buspar" formulation.
  • HPLC-MS assays were performed to determine the concentration of buspirone and 1-pyrimidinylpiperazine (1-PP) in each of the blood plasma samples.
  • the following pharmacokinetic parameters were determined for both analysed substances: bioavailability (as measured as the area under the curve (AUC) of the drug concentration/time plot) and Cmax (the maximum plasma concentration achieved) .
  • Example 1 20 mg 13 . 0 33 . 4 6 . 5 46 . 5 Buspar 20mg 3 . 6 8 . 0 6 . 8 37 . 9
  • compositions of this invention will increase the ratio of the unchanged drug to the main metabolite's area under the plasma concentration-time curve (AUC) by at least 1.5 times and, most preferably, by at least 2 times. Examples 3 to 11

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT1 agonist, characterised in that the composition is formulated to reduce pre-systemic metabolism of said 5-HT1 agonist. A process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders and/or as a memory enhancer are also provided.

Description

PH7ARMACEUTIC7AL COMPOSITION
This invention relates to a pharmaceutical composition, a process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders, sleep apnoea and/or related respiratory disorders and/or substance addiction, especially alcohol abuse, the treatment and/or prophylaxis of incontinence disorders, inducing immunosuppression and/or treating immune disorders, the alleviation of extrapyramidal motor disorders and/or as a memory enhancer.
Buspirone (8- [4- [4- (2-pyrimidinyl) -1- piperazinyl] butyl] -8-azaspiro [ .5] decane-7, 9-dione) has been shown to be effective in the treatment of anxiety. The mechanism of action of buspirone has not been fully elucidated. However, it is known that buspirone is a 5- WI1 agonist and, in particular, a potent 5-HT1A agonist and it is thought that it is action at these receptors which may account for its anxiolytic activity.
Buspirone is currently administered orally in the form of a conventional tablet which is scored in a manner which provides for it to be broken into halves or thirds along breaklines, thus allowing for some titration of the dose. However, each tablet or portion thereof is designed to be swallowed whole. Doses range from 15 to 60 mg per day and may be delivered as 2 or 3 divided doses. When administered in this way, buspirone is absorbed from the gastrointestinal tract, that is, the stomach, the small intestine and the proximal large intestine (colon) , into the hepatic portal system and is presented to the liver before reaching the systemic circulation. The liver is known to be the principal site for conversion of active buspirone into metabolites and, indeed, buspirone is rapidly metabolised by the liver into a large number of metabolites. In a radio-label study in man, twelve metabolites of buspirone were isolated from urine (see H. K. Jajoo et al, Drug Metabolism and Disposition, (1989) , 17., 634-640) . However, only one of these metabolites, 1- pyrimidinylpiperazine (1-PP) , has been reported to possess any potential therapeutic activity and this compound is said to possess, at most, only 20% of the activity of unchanged buspirone as determined by the Vogel conflict test in rats (see R.E. Gammans et al, Am. J.Med. , (1986) , (suppl.3B) , 41-51).
The mean systemic availability of unchanged buspirone is thought to be about 4% after conventional oral administration and the plasma levels of this drug are said to exhibit great variability. This latter effect has been attributed to differences between individuals in pre-systemic metabolism, that is, metabolism in the gastrointestinal tract, in the membranes lining the gastrointestinal tract and also in the liver. However, it is clear that the clinical effectiveness of buspirone is compromised by the extensive pre-systemic metabolism of this drug which occurs following conventional oral administration.
Buspirone is an example from a class of compounds known as the azapirones which have been shown to be effective in the treatment of anxiety. Other azapirones include , 4-dimethyl-1- [4- [4- (2-pyrimidinyl) -1- piperazinyl] butyl] -2 , 6-piperidinedione (gepirone) , 2- [4- [4- (2-pyrimidinyl) -1-piperazinyl] butyl] -1,2- benzisothiazol-3 (2H) -one 1,1-dioxide (ipsapirone) , (3aα,4θ!,4aβ, 6aβ, 7α,7acϋ) -3a, 4 , 4a, 6a, 7, 7a-hexahydro-2- [4- [4- (2-pyrimidinyl) -1-piperazinyl] butyl] -4 , 7-etheno-lH- cyclobut [f] isoindole-1, 3 (2H) -dione (zalospirone) , 3-butyl-7- [4- [4- (2-methoxyphenyl) -1-piperazinyl] butyl] - 9, 9-dimethyl-3 , 7-diazabicyclo [3.3.l]nonane-2, 4,6,8- tetrone (umespirone) , (S) -8- [4- [ (3 , 4-dihydro-5-methoxy- 2H-l-benzopyran-3-yl)propylamino] butyl] -8- azaspiro [4.5] decane-7, 9-dione (alnespirone) , 6- (3- chlorophenoxy) -2-methyl-l-oxa-4-azaspiro [4.5] decan-3-one (enilospirone) , octahydro-3- [4- [4- (2-pyrimidinyl) -1- piperazinyl] butyl] -1, 5-methano-6, 7, 9-metheno-lH-pentaleno [l,2-d]azepine-2,4(3H,5H) -dione (WY-48723) , 4- [4- [4- (2- pyrimidinyl) -1-piperazinyl] butyl] -1 , 4-benzoxazepine-
3,5 (2H,4H) -dione (SUN-8399) , (3aα, 4β, 7β, 7aα) -hexahydro-2 - [4- [4- (2-pyrimidinyl) -1-piperazinyl] butyl] -4, 7-methano- lH-isoindole-1, 3 (2H) -dione 2-hydroxy-l, 2,3- propanetricarboxylate (1:1) (tandospirone) and salts thereof. All these compounds act as agonists at 5-HTx receptors, particularly 5-HT1A receptors, and, like buspirone, are subject to extensive pre-systemic metabolism. Other compounds which interact with 5-HTj. receptors (5-HT-,. agonists) include (+) -N- [2- [4- [2,3-dihydro-2- (hydroxymethyl) -1,4- benzodioxin-5-yl] -1-piperazinyl] ethyl] -4-fluoro- benzamide (flesinoxan) , 2- [4- [4- (4-chloro-lH-pyrazol-l- yl) butyl] -1-piperazinyl] pyrimidine (lesopitron) , (R) -3,4-dihydro-N- (1-methylethyl) -3- ( (l- methylethyDpropylamino) -2H-l-benzopyran-5-carboxamide (ebalzotan) , N- [2- [4- (2-pyrimidinyl) -1- piperazinyl] ] adamantane-1-carboxamide (adatanserin) , (R) - 4- (dipropylamino) -1,3,4, 5-tetrahydro-benz (cd) indole-6- carboxamide (LY-228729) , F-8910-RS, (-) -cis-3-propyl- 2,3,3a(R) , 4 , 5 , 9b-hexahydro-14-benz [e] indole-9-carboxamide (U-93385) , 4- [2- [4- (naphthalen-1-yl) piperazin-1- yl) ethyl] quinolin-2 (1H) one (SL-87.0765) , 2- [4- [4 , 4-bis (4- fluorophenyl) butyl] -l-piperazinyl-3-pyridinecarboxylic acid methyl ester (FG-5893), 4-fluoro-N- [2- [4- [7-methoxy- 1-naphthyl] piperazin-1-yl] ethyl] benzamide (S-14506) , 5- methoxy-3- [4- (4- (4-methoxyphenyl) -1- piperazinyl ) butyl] indole (EMD-56551) , (-) -N- [2- (8-methyl- l,4-benzodioxan-2- ylmethylamino) ethyl] adamantane-1- carboxamide (HT-90B) , F-92502-CN, 2- [4- [4- (4- nitropyrazol-1-yl) butyl] piperazin-1-yl] pyrimidine (E- 4414) , 5- [3- [ [ (2S) -1 , 4-benzodioxan-2-ylmethyl] - amino] propoxy] -1, 3-benzodioxolane (MKC-242), 4-methyl-2- [4- (4- (pyrimidin-2-yl) -piperazino) butyl] -2H, H-1, 2,4- triazin-3,5-dione (F-12439) , l-(2-(4-(3- trifluoromethylphenyl ) piperazin-1-yl) ethyl) benzimidazol-
[lH]-2-one (BIMT-17) , LY-39, SL-88.0338, 1,2,3,6- tetrahydro-1- [2- (2-naphthalenyl) ethyl] -4- [3-
(trifluromethyl)phenyl]pyridine (SR-57746A) , 1- (9H- fluoren-2-yl) -2- (lH-imidazol-1-yl) ethanone (LY-175644) ,
(+/-) trans-2- (4- (3a, 4, 4a, 6a, 7 , 7a-hexahydro-4 , 7-etheno-lH- cyclobut [f] isoindol-1, 3-dionyl) butyl-9-methoxy- 2,3, 3a, 4, 5, 9b-hexahydro-lH-benz [e] isoindole (A-74283),
1,3,4, 5-tetrahydo-6-methoxy-N,N-dipropylbenz [cd] indol-4- amine (Bay-r-1531) , 4- (4-methyl-l-piperazinyl) -7-
(trifluoromethyl) -pyrrolo [1, 2 -a] quinoxaline (Z) -2- butenedioate (1:2) (CGS-12066B) , trans-1, 3 , 4 , 4a, 5 , 10b- hexahydro-10-methoxy-4-propyl-2H- [1] benzopyrano [3 , 4- b]pyridine (CGP-50281) , N-propyl-N- [2- (4- fluorobenzamido) ethyl] amino-5, 6,7, 8-tetrahydroquinoline
( AY-100012) , 3a,4,4a,6a,7,7a-hexahydro-2- [4- [4- (2- pyrimidinyl) -1-piperazinyl] butyl] -4 , 7-ethenocyclobuta [f] - 1, 2-benzisothiazol-3 (2H) -one 1,1-dioxide, cis-7-chloro- 10-methoxy-5a, 10b-dihydro-3N-n-propyl-6H-indeno [1,2- d] azepine, l-cyclohexyl-3- [4- [4- (2, 3-dihydro-2, 2- dimethylbenzofuran-7-yl) -1-piperazinyl] -1-butyl] -2- imidazolidinone, 1- [3-amino-2H-l-benzopyran-2-one-8- yDpiperazine, 4- (1-methylethyl) -2- [3- (trifluoromethyl) - phenyl]mor holine (oxaflozane) , N, 5 -dimethyl-10-dibenz-
(b, f) azepine-ethanamine (RU-5031) , 1, 4-dihydro-3-
(1,2,3, 6-tetrahydro-4-pyridinyl) -5H-pyrrolo [3 , 2-b] - pyridin-5-one (CP-93129) , N-methyl-3- (l-methyl-4- piperidinyl) -lH-indole-5-ethanesulphonamide
(naratriptan) , 3- [3- [4- (5-methoxy-4 -pyrimidinyl) -1- piperazinyl] propyl] -N-methyl-lH-indole-5- methanesulphonamide (avitriptan) , N,N-dimethyl-5- (1H- 1,2,4 -1riazol-1-ylmethyl) -1H-indole-3 -ethanamine (rizatriptan), N- [4- [ [5- [3- (2-aminoethyl) -lH-indol-5-yl] - 1,2,4-oxadiazol-3 -yl] methyl] phenyl] methanesulphonamide
(L-694247) , IS-159, 1- ( ( (3 - (2 - (dimethylamino) ethyl) -1H- indol-5-yl) methyl) sulphonyl) pyrrolidine (almotriptan) , 4- ( (3- (2- (dimethylamino) ethyl) - lH-indol-5-yl) methyl- (S) - 2-oxazolidinone (zolmitriptan) , 3- [2- (dimethylamino) - ethyl] -N-methyl-1H-indole-5-methanesulphonamide (sumatriptan) , 3- ( (1-methyl-2 -pyrrolidinyl) methyl) -5- (2- (phenylsulphonyl) ethyl) - (R) -lH-indole (eletriptan) , (R) - (+) -3- ( ethylamino) -1,2,3, 4-tetrahydro-9H-carbazole- 6-carboxamide (VML-251) , L-0076, ALX-0625, (R) -N-methyl- [3- (1-methyl-2-pyrrolidinyl) -lH-indol-5- yl) methanesulphonamide (CP-122288) , 3- [3- [4- (5, 6- dimethoxypyrimidin-4-yl) piperazin-1-yl] propyl] -N-methyl- lH-indol-5-yl-methylsulphonamide (VS-395) , L-747201, LY-334370 and salts thereof.
It would be highly desirable from a clinical point of view to find a way of administering such 5-HTi agonists so that the bioavailability of the active ingredient is enhanced and the variability in plasma levels caused by differences in pre-systemic metabolism is reduced. According to the present invention there is therefore provided a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HTi agonist, characterised in that the composition is formulated to reduce pre-systemic metabolism of the 5-HTi agonist.
If pre-systemic metabolism of the active ingredient is to be reduced, it is important that the active ingredient is absorbed into the systemic circulation at a site which enables the active ingredient to avoid entering the portal circulation to the liver and thus avoid extensive metabolism by the liver (the so- called "first pass effect"). Since absorption from the gastrointestinal tract is known to result in the active ingredient entering the hepatic portal system to the liver, one option for reduction of pre-systemic metabolism is to promote absorption from sites before the active ingredient reaches the gastrointestinal tract. Accordingly, it is preferred that the composition of the invention is formulated to promote pre-gastric absorption of the 5-HTi agonist.
The term "pre-gastric absorption" is used to refer to absorption of the active ingredient from that part of the alimentary canal prior to the stomach and includes buccal, sublingual, oropharyngeal and oesophageal absorption.
It is envisaged that such pre-gastric absorption will occur primarily across the mucous membranes in the mouth, pharynx and oesophagus. Accordingly, it is preferred that the composition of the invention is formulated to promote absorption of the active ingredient through the buccal, sublingual, pharyngeal and/or oesophageal mucous membranes.
It is therefore preferred that the composition of the invention should be in a form which sustains the active ingredient in contact with the buccal, sublingual, pharyngeal and/or oesophageal mucous membranes . Preferably, the composition of the invention is in the form of a viscous emulsion, syrup or elixir, a sub-lingual tablet, a suckable or chewable tablet, softgel, lozenge, aqueous or non-aqueous drops or other dosage form designed to release the active ingredient in a controlled manner to saliva or to the buccal, pharyngeal and/or oesophageal mucous membranes, a fast- dispersing dosage form designed rapidly to release the active ingredient in the oral cavity, or a bioadherent system. The term "bioadherent system" refers to a solid or liquid dosage form which, at body temperature, exhibits controlled release and bioadherence characteristics. This type of dosage form may be an emulsion which is water in oil in nature and whose internal phase is greater than that of the external phase. Examples of such bioadherent systems may be found in U.S. Patent No. 5055303. Of the dosage forms listed above, fast-dispersing dosage forms are particularly preferred since they will disintegrate rapidly in the mouth without the need for water, or other liquid, to aid swallowing. Such fast- dispersing dosage forms are therefore more convenient and easier for patients to take than conventional oral dosage forms. Also, since no water, or other liquid, is required to take such fast-dispersing dosage forms, the active ingredient is presented for absorption at a higher concentration than with conventional oral dosage forms. Thus, use of such fast-dispersing dosage forms may allow a reduction in the dose required to achieve the desired therapeutic effect which, in turn, may result in a reduction in the incidence and/or severity of side effects. More reproducible plasma levels of the active ingredient may also be achieved with such dosage forms.
Since such fast-dispersing dosage forms produce a concentrated solution of the active ingredients in the saliva of the mouth, it is also possible that, when swallowed, this concentrated solution coats the stomach mucosa more effectively than a conventional drug dissolved in water and this may increase the rate of absorption of the active ingredient. Moreover, absorption from the highest part of the stomach may also by-pass the hepatic portal vein and hence produce a higher level of the active ingredient in the plasma.
One example of a fast-dispersing dosage form is described in U.S. Patent No. 4855326 in which a melt spinnable carrier agent, such as sugar, is combined with an active ingredient and the resulting mixture spun into a "candy-floss" preparation. The spun "candy-floss" product is then compressed into a rapidly dispersing, highly porous solid dosage form.
U.S. Patent No. 5120549 discloses a fast- dispersing matrix system which is prepared by first solidifying a matrix-forming system dispersed in a first solvent and subsequently contacting the solidified matrix with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, the matrix- forming elements and active ingredient being substantially insoluble in the second solvent, whereby the first solvent is substantially removed resulting in a fast-dispersing matrix.
U.S. Patent No. 5079018 discloses a fast- dispersing dosage form which comprises a porous skeletal structure of a water soluble, hydratable gel or foam forming material that has been hydrated with water, rigidified in the hydrated state with a rigidifying agent and dehydrated with a liquid organic solvent at a temperature of about 0°C or below to leave spaces in place of hydration liquid.
Published International Application No. WO 93/12769 (PCT/JP93/01631) describes fast-dispersing dosage forms of very low density formed by gelling, with agar, aqueous systems containing the matrix-forming elements and active ingredient, and then removing water by forced air or vacuum drying.
U.S. Patent No. 5298261 discloses fast-dispersing dosage forms which comprise a partially collapsed matrix network that has been vacuum-dried above the collapse temperature of the matrix. However, the matrix is preferably at least partially dried below the equilibrium freezing point of the matrix.
Published International Application No. WO 91/04757 (PCT/US90/05206) discloses fast-dispersing dosage forms which contain an effervescent disintegration agent designed to effervesce on contact with saliva to provide rapid disintegration of the dosage form and dispersion of the active ingredient in the oral cavity. U.S. Patent No. 5595761 discloses a particulate support matrix for use in making a rapidly dissolving tablet, comprising; a first polypeptide component having a net charge when in solution, e.g. non-hydrolysed gelatin; a second polypeptide component having a net charge of the same sign as the net charge of the first polypeptide component when in solution e.g. hydrolysed gelatin; and a bulking agent , and wherein the first polypeptide component and the second polypeptide component together comprise about 2% to 20% by weight of the particulate support matrix and wherein the bulking agent comprises about 60% to 96% by weight of the particulate support matrix; and wherein the second polypeptide component has a solubility in aqueous solution greater than that of the first polypeptide component and wherein the mass: mass ratio of the first polypeptide component to the second polypeptide component is from about 2 : 1 to about 1 : 14 ; and wherein when the support matrix is introduced into an aqueous environment the support matrix is disintegrable within less than about 20 seconds.
US Patent No. 5576014 discloses fast-dispersing dosage forms which dissolve intrabuccally and which comprise compressed moldings formed from granules comprising a saccharide having low moldability which has been granulated with a saccharide having high moldability. The resulting compressed moldings show quick disintegration in the buccal cavity.
EP-B-0690747 describes particles comprising an excipient forming a matrix and at least one active ingredient uniformly distributed in the mass of the matrix which are prepared by a process comprising the steps of preparing an homogeneous pasty mixture with a viscosity below 1 Pa . s , measured at room temperature (15- 20°C) , from at least one active ingredient, a physiologically acceptable hydrophilic excipient and water; extruding the resulting homogeneous mixture and cutting the extrudate to give moist particles; freezing the resulting particles as they fall under gravity through a stream of inert gas at a temperature below 0°C; and drying the particles by freeze drying.
Australian Patent No. 666666 discloses a rapidly disintegratable multiparticulate tablet having a mixture of excipients in which the active substance is present in the form of coated microcrystals or optionally coated microgranules . Such tablets disintegrate in the mouth in an extremely short time, typically less than 60 seconds. US Patent No. 5382437 discloses a porous carrier material having sufficient rigidity for carrying and administering an active material which is capable of rapid dissolution by saliva and which is formed by freezing a liquefied ammonia solution comprising liquid ammonia, a liquid ammonia-soluble gel or foam material and a rigidifying agent for the gel or foam material selected from the group consisting of a monosaccharide, a polysaccharide and combinations thereof, and deammoniating the frozen material thus formed by causing material transfer of ammonia from the frozen state to the gas state thereby leaving spaces in the carrier material in place of the frozen ammonia.
Published International Application No. WO 93/13758 (PCT/US92/07497) describes tablets of increased physical strength which are prepared by combining and compressing a meltable binder, excipients and a pharmaceutically active agent into a tablet, melting the binder in the tablet and then solidifying the binder. In one embodiment, a disintegrating agent is utilised to increase the disintegration rate of the tablet after oral intake. In another embodiment, a volatilisable component is used to form porous tablets. Some embodiments disintegrate in the mouth in less than 10 seconds.
US Patents Nos . 3885026 and 4134943 also disclose fast-dispersing porous tablets and a method for increasing their physical strength by first compressing the tablet and then volatilising a readily volatilisable solid adjuvant incorporated in the tablet to attain the desired porosity.
EP-A-0601965 describes a shearform matrix material which can be used, inter alia, to deliver a pharmaceutically active agent. The shearform matrix is formed by increasing the temperature of a feedstock which includes a solid non-solubilised carrier material to the point where it will undergo internal flow with the application of a fluid shear force, ejecting a stream of the heated feedstock thus formed under pressure from an orifice and then subjecting the feedstock to disruptive fluid shear force which separates the flow of feedstock into multiple parts and transforms the morphology of the feedstock . US Patent No. 5683720 discloses discrete particles containing a pharmaceutically active agent which can be fast-dispersing and are formed by subjecting a solid, organic feedstock to liquiflash conditions whereby the feedstock is transformed instantaneously from solid to liquiform to solid, liquiform being a transient condition in which the feedstock has substantially unimpeded internal flow. Shear force is then imparted to the liquiform feedstock in an amount sufficient to separate tiny masses of feedstock which then solidify as discrete particles.
The term "fast-dispersing dosage form" therefore encompasses, but is not limited to, all the types of dosage form described in the preceding paragraphs . However, it is particularly preferred that the fast- dispersing dosage form is of the type described in U.K. Patent No. 1548022, that is, a solid fast-dispersing dosage form comprising a network of the active ingredient and a water-soluble or water-dispersible carrier which is inert towards the active ingredient, the network having been obtained by subliming solvent from a composition in the solid state, that composition comprising the active ingredient and a solution of the carrier in a solvent . It is preferred that the composition of the invention disintegrates within 1 to 60 seconds, more preferably 1 to 30 seconds, especially 1 to 10 seconds, and particularly 2 to 8 seconds, of being placed in the oral cavity.
In the case of the preferred type of fast- dispersing dosage form described above, the composition will preferably contain, in addition to the active ingredient, matrix forming agents and secondary components. Matrix forming agents suitable for use in the present invention include materials derived from animal or vegetable proteins, such as the gelatins, dextrins and soy, wheat and psyllium seed proteins; gums such as acacia, guar, agar, and xanthan; polysaccharides; alginates; carboxymethylcelluloses; carrageenans; dextrans; pectins; synthetic polymers such as polyvinylpyrrolidone; and polypeptide/protein or polysaccharide complexes such as gelatin-acacia complexes . Other matrix forming agents suitable for use in the present invention include sugars such as mannitol, dextrose, lactose, galactose and trehalose; cyclic sugars such as cyclodextrin; inorganic salts such as sodium phosphate, sodium chloride and aluminium silicates; and amino acids having from 2 to 12 carbon atoms such as a glycine, L-alanine, L-aspartic acid, L-glutamic acid, - hydroxyproline, L-isoleucine, L-leucine and L- phenylalanine .
One or more matrix forming agents may be incorporated into the solution or suspension prior to solidification. The matrix forming agent may be present in addition to a surfactant or to the exclusion of a surfactant. In addition to forming the matrix, the matrix forming agent may aid in maintaining the dispersion of any active ingredient within the solution or suspension. This is especially helpful in the case of active agents that are not sufficiently soluble in water and must, therefore, be suspended rather than dissolved.
Secondary components such as preservatives, antioxidants, surfactants, viscosity enhancers, colouring agents, flavouring agents, pH modifiers, sweeteners or taste-masking agents may also be incorporated into the composition. Suitable colouring agents include red, black and yellow iron oxides and FD & C dyes such as FD & C blue No. 2 and FD & C red No. 40 available from Ellis & Everard. Suitable flavouring agents include mint, raspberry, liquorice, orange, lemon, grapefruit, caramel, vanilla, cherry and grape flavours and combinations of these. Suitable pH modifiers include citric acid, tartaric acid, phosphoric acid, hydrochloric acid and maleic acid. Suitable sweeteners include aspartame, acesulfame K and thaumatin. Suitable taste-masking agents include sodium bicarbonate, ion-exchange resins, cyclodextrin inclusion compounds, adsorbates or microencapsulated actives.
Preferred compositions in accordance with this invention include a 5-HT1A agonist, especially an azapirone or a salt thereof, as the active 5-HTi agonist. It is particularly preferred that the active 5-HTi agonist is buspirone or a salt thereof.
Buspirone which is absorbed by pre-gastric absorption or at a high rate across the stomach mucosa from a composition in accordance with this invention passes straight into the systemic circulatory system thereby avoiding first pass metabolism in the liver. Accordingly, the initial rapid production of unwanted, inactive metabolites is reduced and the bioavailability of active buspirone is increased. This results in a number of advantages. For instance, the increased bioavailability of active buspirone means that the dose of buspirone may be reduced whilst still producing the desired beneficial effect. This will result in a further decrease in the production of unwanted metabolites and a reduction in the incidence and/or severity of side effects .
In the case of buspirone, the active ingredient preferably is present in the composition in an amount of from 0.5 to 30%, more preferably 1 to 20%, by weight of the composition. It is also preferred that the active ingredient is present in the composition in an amount of from 0.25 to 50 mg, more preferably 0.5 to 10 mg and, especially, 1 to 10 mg.
In the case of other 5-HTi agonists, these also will be present in concentrations which are clinically effective.
According to another aspect of the invention there is provided a process for preparing a pharmaceutical composition as defined above which comprises bringing a carrier into association with the active ingredient.
In a further aspect, the invention provides the use of a fast-dispersing dosage form designed to release active ingredient rapidly in the oral cavity to deliver a 5-HTj. agonist. A method of administering a 5-HTi agonist to a patient which comprises introducing into the oral cavity of the patient a composition as previously defined is also provided.
The invention also provides, in another aspect, a composition as defined above for use in the treatment of anxiety. The composition of the invention is also useful in the palliative treatment of anxiety neurosis, that is, neurosis with a preponderance of anxiety symptoms.
5-HTi agonists, especially the azapirones, have also been evaluated in the treatment of depression, attention deficit disorder and panic disorders and as memory enhancers. Also, the azapirones, especially buspirone, have been found to be useful in the treatment and/or prophylaxis of incontinence disorders associated with the gastrointestinal or urogenital tracts, such as urinary incontinence, faecal incontinence and urinary retention. Such compounds are also useful for inducing immunosuppression and/or treating immune disorders and are therefore useful in the treatment of conditions such as contact, atopic or eczematous dermatitis and Sjogren's syndrome (including secondary keratoconjunctivitis sicca) , autoimmune diseases and diseases of known or unknown etiology having an immunological component or allergies, especially rheumatoid arthritis and, in particular, juvenile rheumatoid arthritis. Such compounds may also be used in the treatment of sleep apnoea and related respiratory disorders, such as sudden infant death syndrome, and can also alleviate the symptoms of sleep apnoea such as anxiety, depression, fatigue, malaise, irritability, anger and hostility.
In addition, azapirones such as buspirone can be used in the treatment of substance addiction. In this respect, substance addiction includes over-eating, eating disorders and the habitual use of alcohol, tobacco, marijuana, cocaine, opiates, methadone, amphetamine, methphenidate and related designer drugs. Such compounds are particularly useful in the treatment of alcohol abuse as they also reduce the craving for alcohol and can therefore be used for treating patients undergoing short term treatment of alcohol withdrawal and in chronic alcohol abusers . Use of such compounds in the treatment of alcohol abuse avoids the enhancement or continuation of sensory impairment, the risk of developing drug dependence and the unpleasant effects of so-called aversion therapy. Moreover, such compounds produce behavioural modifications which include lessening of alcohol craving and ingestion and improvement of social functioning. In addition, psychogenic symptoms, such as illness, anxiety, depression, clouded sensorium, hostility, violence and decreased cognition, are alleviated. Azapirones, particularly buspirone, are also useful for the alleviation of extrapyramidal motor disorders and can therefore be used to treat such conditions as Parkinson's disease, neuroleptic-induced extrapyramidal symptoms and tardive dyskinesia.
In addition to the above conditions, 5-HTi agonists have also been used in the treatment of social phobia, obsessive-compulsive disorder, migraine, cerebellar ataxia, levodopa-induced dyskinesias, Huntington's disease, central and peripheral neurodegenerative disorders, emesis, hypertension, hayfever, asthma and pruritis and to assist smokers in giving up smoking.
Of the 5-HTi agonists other than the azapirones, the 5-HT1D agonists have been found to be especially useful in the treatment of migraine and related conditions . According to a further aspect of the invention there is therefore provided the use of a composition as defined above for the manufacture of a medicament for the treatment of depression, attention deficit disorder, panic disorders, sleep apnoea and/or related respiratory disorders and/or substance addiction, especially alcohol abuse, the treatment and/or prophylaxis of incontinence disorders, inducing immunosuppression and/or treating immune disorders, the alleviation of extrapyramidal motor disorders and/or as a memory enhancer. This invention is further illustrated by the following examples.
Example 1.
Preparation of a fast-dispersing dosage form of buspirone hydrochloride
(a) Preparation of buspirone hydrochloride 2.0% dispersion Gelatin (720g) and mannitol (540g) were dispersed in a portion of purified water (16kg) by mixing thoroughly in the bowl of a vacuum mixer. The mix was then heated to 40°C ± 2°C and homogenised for ten minutes. The mix was cooled down to room temperature (20-24 °C) . When cooled the glycine (180g) and buspirone hydrochloride (360g) was added. The mix was homogenised to ensure dissolution of glycine and the drug. Citric acid (54g) was added gradually with stirring, to adjust the solution pH to 4.0. The remaining water (146g) was added to the mixer and the bulk mix homogenised to ensure dissolution was complete . (b) Preparation of buspirone hydrochloride lOmg units 500mg of the buspirone hydrochloride 2.0% dispersion formed in (a) above was dosed into each one of a series of pre-formed blister pockets having a pocket diameter of 16mm. The blister laminate comprised 200μm PVC coated with 40gsm PVdC. The product was frozen immediately in a liquid nitrogen freeze tunnel. The frozen product was then stored below -18°C for a minimum of 40 hours prior to freeze-drying in a freeze drier using a drying temperature of +20°C and a chamber pressure of 0.5 mbar. The freeze dried units were then inspected for the presence of critical defects and the remainder of the batch sealed with lidding foil consisting of a paper/foil laminate (20μm aluminium) .
Each blister was then coded with a batch number and overwrapped in a preformed sachet by placing the blister in the sachet and sealing the open end of the sachet completely. Each sachet was then labelled with the product name, batch number, date of manufacture and suppliers name. Each dosage unit had the following composition:
♦Signi ies remove ur ng t e yop i isation process
Example 2
Comparative pharmacokinetic study
The aim of this experiment was to compare the bioavailability of the buspirone hydrochloride formulation of Example 1 with the commercially available tablet formulation of buspirone hydrochloride sold under the registered Trade Mark "Buspar" by Bristol-Myers Pharmaceuticals, Bristol-Myers Squibb House, 141-149 Staines Road, Hounslow, Middlesex, TW3 3JA, England.
An open label, randomised, crossover, volunteer study was performed as follows. Six fasted, healthy male subjects of ages between 18 and 40 years, giving written informed consent, underwent a thorough medical examination to establish their fitness to participate in the study. Subjects received study treatment in the order dictated by a pre-determined randomisation schedule. Subjects were given either the formulation of Example 1 or the "Buspar" formulation. Blood samples for determination of pharmacokinetic parameters were taken at baseline (immediately before drug administration) , then after 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 12 and 24 hours. The study procedures were repeated two weeks later, when subjects were crossed-over to receive their second drug administration. Buspirone hydrochloride was administered as single 20 mg doses (made up from 2 x 10 mg tablets) of the formulation of Example 1 or of the "Buspar" formulation. HPLC-MS assays were performed to determine the concentration of buspirone and 1-pyrimidinylpiperazine (1-PP) in each of the blood plasma samples. The following pharmacokinetic parameters were determined for both analysed substances: bioavailability (as measured as the area under the curve (AUC) of the drug concentration/time plot) and Cmax (the maximum plasma concentration achieved) .
The results are shown in graphical form in Figures 1 and 2 where each figure is a plot of the concentration of a specific compound in a blood plasma sample versus the time at which the sample was taken for the formulation of Example 1 (Example 1) and the tablet formulation sold under the registered Trade Mark "Buspar" (Buspar) . In Figure 1, the specific compound is buspirone. In Figure 2, the specific compound is 1- pyrimidinylpiperazine (1-PP) .
The mean results are shown in numerical form in Table 1 below.
TABLE 1
Buspirone 1- PP
C aχ AUC (0.24hr) nax •"UC (0.24hr)
(ng/ml ) (ng/ml . hr) (ng/ml ) (ng/ml . hr)
Example 1 , 20 mg 13 . 0 33 . 4 6 . 5 46 . 5 Buspar 20mg 3 . 6 8 . 0 6 . 8 37 . 9
From Figures 1 and 2 and Table 1, it is apparent that the bioavailability of buspirone from the formulation of Example 1 is about four times that of buspirone from the "Buspar" formulation despite the fact that both formulations contained the same amount of active ingredient. Also, the bioavailability of 1- pyrimidinylpiperazine (1-PP) is very similar for both formulations. However, in view of the much greater bioavailability of buspirone from the formulation of Example 1, it is envisaged that the dose of buspirone could be significantly reduced thereby significantly reducing the quantity of unwanted metabolites and the incidence or severity of side effects whilst still achieving the desired levels of buspirone in plasma and hence the desired therapeutic effect associated with this compound .
In Table 1, the ratio of the area under the plasma concentration-time curve (AUC) for buspirone and the AUC for 1-PP was 0.211 for the "Buspar" formulation, indicating clearly the extensive metabolism of buspirone when administered in a conventional tablet form. The corresponding AUC ratio for Example 1 in Table 1 was 0.718. This demonstrates that administration in the formulation of Example 1 results in a greater proportion of the administered dose of buspirone being absorbed in the unmetabolised form and, indeed, it is apparent from Figure 2 that metabolism of buspirone occurs more slowly for the formulation of Example 1 since the maximum amount of 1-PP for the formulation of Example 1 is observed about 2 hours later than that for the conventional "Buspar" formulation.
Pharmaceutical compositions of this invention will increase the ratio of the unchanged drug to the main metabolite's area under the plasma concentration-time curve (AUC) by at least 1.5 times and, most preferably, by at least 2 times. Examples 3 to 11
The following additional fast-dispersing dosage forms may be prepared according to the method of Example 1:- Example 3
♦S gn es remove ur ng t e yop sat on process
Example 4
♦Sign fies remove uring t e yop i isation process
Example 5
♦S gn f es remove ur ng t e yop sat on process Example 6
♦Signif es remove ur ng t e yop sat on process
Example 7
♦S gnif es remove ur ng t e yop sat on process
Example 8
♦Signifies remove ur ng t e yop sat on process Example 9
♦Signi ies remove ur ng t e yop isation process.
Example 10
♦Signifies removed during the lyophilisation process,
Example 11
♦Signifies removed during the lyophilisation process

Claims

1. A pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HTx agonist, characterised in that the composition is formulated to reduce pre-systemic metabolism of said 5-HTi agonist.
2. A composition according to claim 1 in which the composition is formulated to promote pre-gastric absorption of said 5-HTi agonist.
3. A composition according to claim 1 or claim 2 in which the composition is formulated to promote absorption of said 5-HTi agonist through the buccal, sublingual, pharyngeal and/or oesophageal mucous membrane.
4. A composition according to claim 1 in which the composition is formulated to promote absorption of said
5-HTi agonist through the stomach mucous membrane.
5. A composition according to any one of the preceding claims in which the 5-HTi agonist is selected from buspirone, gepirone, ipsapirone, zalospirone, umespirone, alnespirone, enilospirone, WY-48723, SUN- 8399, tandospirone , flesinoxan, lesopitron, ebalzotan, adatanserin, LY-228729, F-8910-RS, U-93385, SL-87.0765, FG-5893, S-14506, EMD-56551, HT-90B, F-92502-CN, E-4414, MKC-242, F-12439, BIMT-17, LY-39, SL-88.0338, SR-57746A, LY-175644, A-74283, Bay-r-1531, CGS-12066B, CGP-50281, WAY-100012, 3a,4,4a,6a,7,7a-hexahydro-2- [4- [4- (2- pyrimidinyl) -1- [piperazinyl] butyl] -4,7- ethenocyclobuta [f] -1, 2-benzisothiazol-3 (2H) -one 1, 1- dioxide, cis-7-chloro-10-methoxy-5a 10b-dihydro-3N-n- propyl-6H-indeno [1, 2-d] azepine, l-cyclohexyl-3- [4- [4- (2, 3-dihydro-2, 2-dimethylbenzofuran-7-yl) -1-piperazinyl] - 1-butyl] -2-imidazolidinone, 1- [3-amino-2H-l-benzopyran-2- one-8-yl]piperazine, oxaflozane, RU-5031, CP-93129, naratriptan, avitriptan, rizatriptan, L-694247, IS-159, almotriptan, zolmitriptan, sumatriptan, eletriptan, VML-251, L-0076, ALX-0625, CP-122288, VS-395, L-747201, LY-334370 and salts thereof.
6. A composition according to any one of the preceding claims in which the 5-HTi agonist is a 5-HT1A agonist.
7. A composition according to claim 6 in which the 5-HTi agonist is selected from buspirone, gepirone, ipsapirone, zalospirone, umespirone, alnespirone, enilospirone, WY-48723, SUN-8399, tandospirone and salts thereof .
8. A composition according to claim 7 in which the 5-HTi agonist is buspirone or a salt thereof.
9. A composition according to any one of the preceding claims in which the active ingredient is present in an amount of from 0.5 to 30% by weight of the composition.
10. A composition according to any one of the preceding claims in which the active ingredient is present in an amount of 0.25 to 50 mg.
11. A composition according to any one of the preceding claims in which the composition is in the form of a viscous emulsion, syrup or elixir, a sublingual tablet, a suckable or chewable tablet, softgel, lozenge, aqueous or non-aqueous drops or other dosage form designed to release the active ingredient in a controlled manner to saliva or to the buccal, pharyngeal and/or oesophageal mucous membranes, a fast-dispersing dosage form designed rapidly to release the active ingredient in the oral cavity, or a bioadherent system.
12. A composition according to claim 11, in which the composition is in the form of a solid fast-dispersing dosage form comprising a network of the active ingredient and a water-soluble or water-dispersible carrier which is inert towards the active ingredient, the network having been obtained by subliming solvent from a composition in the solid state, that composition comprising the active ingredient and a solution of the carrier in a solvent.
13. A composition according to claim 11 or claim 12, in which the composition disintegrates within 1 to 10 seconds of being placed in the oral cavity.
14. A pharmaceutical composition for oral administration comprising a carrier, and buspirone as an active ingredient, characterised in that the composition is in the form of a solid fast-dispersing dosage form comprising a network of buspirone and a water-soluble or water-dispersible carrier which is inert towards buspirone, the network having been obtained by subliming solvent from a composition in the solid state, that composition comprising buspirone and a solution of the carrier in a solvent .
15. A pharmaceutical composition for oral administration comprising buspirone in a solid fast- dispersing dosage form which disintegrates within 1 to 10 seconds of being placed in the oral cavity.
16. A composition as defined in any one of the preceding claims for use in the treatment of anxiety.
17. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the treatment of depression.
18. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the treatment of Attention Deficit Disorder With or Without Hyperactivity.
19. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the treatment of panic disorders.
20. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for use as a memory enhancer.
21. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the palliative treatment of anxiety neurosis.
22. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the treatment and/or prophylaxis of incontinence disorders .
23. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for inducing immunosuppression and/or treating immune disorders .
24. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the treatment of sleep apnoea and/or related respiratory disorders .
25. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the treatment of substance addiction.
26. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the treatment of alcohol abuse.
27. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the alleviation of extrapyramidal motor disorders.
28. A process for preparing a pharmaceutical composition according to any one of claims 1 to 16 which comprises bringing a carrier into association with said active ingredient.
29. Use of a fast-dispersing dosage form designed to release active ingredient rapidly in the oral cavity to deliver a 5-H i agonist.
EP98912622A 1997-03-24 1998-03-24 Pharmaceutical composition Withdrawn EP0969842A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9706089.1A GB9706089D0 (en) 1997-03-24 1997-03-24 Pharmaceutical composition
GB9706089 1997-03-24
PCT/GB1998/000885 WO1998042344A1 (en) 1997-03-24 1998-03-24 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
EP0969842A1 true EP0969842A1 (en) 2000-01-12

Family

ID=10809779

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98912622A Withdrawn EP0969842A1 (en) 1997-03-24 1998-03-24 Pharmaceutical composition

Country Status (5)

Country Link
EP (1) EP0969842A1 (en)
JP (1) JP2001518925A (en)
AU (1) AU6740298A (en)
GB (1) GB9706089D0 (en)
WO (1) WO1998042344A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904911D0 (en) * 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6268368B1 (en) * 2000-03-01 2001-07-31 American Pharmaceuticals International Anionic exchange polymer complexes of buspirone
ES2267627T3 (en) 2001-05-11 2007-03-16 Jurgen K. Dr. Beck FLIBASERINE FOR THE TREATMENT OF ESTRAPIRAMIDAL MOVEMENT DISORDERS.
US8106074B2 (en) 2001-07-13 2012-01-31 Pierre Fabre Medicament Pyridin-2-yl-methylamine derivatives for treating opiate dependence
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (en) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Medicines with neuroprotective effects
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
WO2004069339A1 (en) * 2003-01-29 2004-08-19 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
JP2007510629A (en) * 2003-10-22 2007-04-26 イーライ リリー アンド カンパニー Novel MCH receptor antagonist
AR049478A1 (en) * 2004-03-25 2006-08-09 Solvay Pharm Bv A PROCEDURE FOR THE PREPARATION OF 3-AMINO-8- (1-PIPERAZINIL) -2H-1-BENZOPIRAN-2-ONA. SALTS AND HYDRATES AND PHARMACEUTICAL COMPOSITIONS.
DE602005023742D1 (en) * 2004-07-15 2010-11-04 Abbott Healthcare Products Bv Formulation of 3-amino-8- (1-piperazinyl) -2H-1-benzene-2-one with delayed release
JP2008511569A (en) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング How to treat attention-deficit hyperactivity disorder
JP2008540356A (en) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Drug abuse treatment methods
US20060258640A1 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
JP2009503020A (en) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of flibanserin in the treatment of obesity
JP2009513604A (en) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazolone derivatives for the treatment of premenstrual disorders and other female sexual disorders
EP1988898A2 (en) * 2006-02-18 2008-11-12 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
WO2007096300A1 (en) * 2006-02-20 2007-08-30 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of urinary incontinence
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
EP2026813A2 (en) * 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
DE602007004615D1 (en) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma FLIBANSERIN FOR THE TREATMENT OF HARNINE INCONTINENCE AND ASSOCIATED DISEASES
KR20090042967A (en) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 Formulations of flibanserin and method for manufacturing the same
AU2007287639A1 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
CN1915233B (en) * 2006-08-30 2012-10-03 四川科瑞德制药有限公司 Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation
PE20091188A1 (en) 2007-09-12 2009-08-31 Boehringer Ingelheim Int COMPOUND 1- [2- (4- (3-TRIFLUOROMETIL-PHENYL) PIPERAZIN-1-IL) ETHYL] -2,3-DIHYDRO-1H-BENZIMIDAZOL-2-ONA (FLIBANSERIN), ITS ADDITION SALTS AND PHARMACEUTICAL COMPOSITIONS THAT THEY CONTAIN
RU2611376C2 (en) * 2010-10-15 2017-02-21 Контера Фарма Апс Pharmaceutical composition for treating, preventing or relieving movement disorders and its application
CN113880815B (en) * 2020-07-03 2024-03-29 中国药科大学 Indole derivatives, preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486666B1 (en) 1990-06-07 1997-08-13 Zeneca Limited Therapeutic heterocyclic compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
US4687772A (en) * 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
JPS63250318A (en) * 1987-04-06 1988-10-18 Fujimoto Seiyaku Kk Pharmaceutical preparation suitable in oral cavity
SE8704097D0 (en) * 1987-10-22 1987-10-22 Astra Ab ORAL FORMULATION OF BUSPIRONE AND SALTS THEREOF
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
JPH04360826A (en) * 1991-06-07 1992-12-14 Bayer Yakuhin Kk Controlled release pharmaceutical preparation
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
DE69222006T2 (en) * 1991-10-30 1998-01-22 Glaxo Group Ltd Multilayer compositions containing histamine or serotonin antagonists
US5246711A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating dysthymia
US5246710A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating cyclothymia
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
DE4319760A1 (en) * 1993-06-15 1994-12-22 Bayer Ag Ipsapiron drug preparation
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
CN1230123A (en) * 1996-07-11 1999-09-29 荷兰发马克有限公司 Inclusion complex containing indole selective serotonin agonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486666B1 (en) 1990-06-07 1997-08-13 Zeneca Limited Therapeutic heterocyclic compounds

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
C.J. THOMSON (STUDY COORDINATOR): "A study to compare oral sumatriptan with oral aspirin plus Oral Metoclopramide in the Acute Treatment of Migraine", EUR NEUROL, vol. 32, no. 3, 1992, pages 177 - 184, XP008095009
DOENICKE A. ET AL.: "Effective improvement of symptoms in patients with acute migraine by GR43175 administered in dispersible tablets", CEPHALALGIA, vol. 9, no. SUPPL.9, 1989, pages 89 - 92, XP008094994
J. P. PATTEN AND THE ORAL SUMATRIPTAN DOSE-DEFINING STUDY GROUP: "Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study", J NEUROL, vol. 238, no. SUPPL.1, February 1991 (1991-02-01), pages 1432 - 1459, XP008094995
LACEY L.F. ET AL.: "Single dose pharmacokinetics of sumatriptan in healthy volunteers", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 47, no. 6, February 1995 (1995-02-01), pages 543 - 548, XP008094998
See also references of WO9842344A1
UNITED STATES PHARMACOPEIAL CONVENTION: "THE UNITED STATES PHARMACOPEIA. THE NATIONAL FORMULARY", 2006, UNITED STATES PHARMACOPEIAL CONVENTION, US, ISBN: 1-889788-47-3, pages: 629, XP003019579
YUNXIA BI; ET AL: "PREPARATION AND EVALUATION OF A COMPRESSED TABLET RAPIDLY DISINTEGRATING IN THE ORAL CAVITY", CHEM. PHARM. BULL., vol. 44, no. 11, 1996, pages 2121 - 2127, XP000636227

Also Published As

Publication number Publication date
GB9706089D0 (en) 1997-05-14
AU6740298A (en) 1998-10-20
JP2001518925A (en) 2001-10-16
WO1998042344A1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
US20040023948A1 (en) Fast-dispersing dosage form containing 5-HT1 agonists
EP0969842A1 (en) Pharmaceutical composition
US6946141B2 (en) As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation
JP5179757B2 (en) Composition for delivering a hypnotic agent through the oral mucosa and method of use thereof
AU717337B2 (en) Dosage forms and method for ameliorating male erectile dysfunction
WO2000020033A1 (en) Tablets immediately disintegrating in the oral cavity
BR112020011238A2 (en) FORMULATION OF SOLID ORAL NICOTIN TO RELIEVE DESIRE OF NICOTINE QUICK START, FORMULATION OF SOLID ORAL NICOTINE FOR USE IN ATTENUING NICOTIN DESIRE, METHOD OF ATTENUATING NICOTIN DESIRE AND ORAL PURSE
AU702161B2 (en) Pharmaceutical compositions comprising monoamine oxidase B inhibitors
JPWO2005037254A1 (en) Tablet Quickly Disintegrating in Oral Cavity
PT833619E (en) CONTROLLED DRUG LIBERALIZATION BY SUBLINGUAL OR ORAL ADMINISTRATION
EP1961413A1 (en) Rapidly disintegratable oral tablet
US20030022910A1 (en) Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine
CA3200444A1 (en) Solid pharmaceutical compositions and methods of producing the same
CA2556450C (en) Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
JP2003261439A (en) Preparation disintegrating in oral cavity
US9675551B2 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
US10111832B2 (en) Orodispersible tablets obtained by compression molding
WO2021171318A1 (en) Transmucosal pharmaceutical composition of levocetirizine
US20030198669A1 (en) Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
Gujarati Oral Disintegrating Tablets: Background and Review on Recent Advancements
EP4311543A1 (en) Methods for loading template inverted carriers
EP2566452A1 (en) Melting tablet comprising a triptane or atypical neuroleptic
TW200423929A (en) Pharmaceutical combination
WO2024047352A1 (en) An orodispersible pharmaceutical composition of fexofenadine and its process of preparation.
BRPI0403668B1 (en) PHARMACEUTICAL COMPOSITIONS OF ORAL DISINTEGRATION WITH HIGH ASPARTAME CONCENTRATIONS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990902

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: R.P. SCHERER TECHNOLOGIES, INC.

17Q First examination report despatched

Effective date: 20010518

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081218